NEKTAR THERAPEUTIC SYSTS TOP ERGEBNIS!!!!!!! - 500 Beiträge pro Seite

[knudeln]

Hallo,
wer hat Infos zu diesem Unternehmen.Empfehlung aus dem Global Biotech: Wiederum glänzende Quartalszahlen konnte gestern nach Börsenschluss dieses US-Biotech-Unternehmen vorlegen: Der Umsatz stieg um knapp 25 Prozent auf 27,8 Millionen US-Dollar (erwartet waren 25,3 Millionen). Entscheidend ist jedoch, dass das erwartete Quartalsergebnis mit gerade 23 Cent Verlust um die Hälfte unterboten wurde. Laut Global Biotech Daily dürfte dies in den USA für kräftig steigende Kurse sorgen.Momentan 12% im
Amiland im Plus.Kursziel für die nächsten 4 Wochen 15 Dollar.Ich habe in Frankfurt mal eine erste Position zugelegt.Wer hat noch Infos über die Firma.

Gruß Knudeln:

[leonide]

Guten Tag,
halte selber eine kleine Position und warte schon eine ganze Zeit, dass sich endlich was (positives) tut. Inhalierbare Medikamente haben für viele Patienten gegenüber Tabletten oder gar Injektionen einen besonderen Reiz. Größere Pharmafirmen brauchen die Zusammenarbeit mit einem Spezialisten wie Nektar. Das "Gesamtpaket" Nektar ist dadurch auch für Anleger im Biotechbereich interessant, insbesondere mit Blick auf die Pipline.

#knudeln
Dir ist das sicher schon bekannt, zum Nachlesen für die Allgemeinheit empfehlenswert: www.nektar.com

[knudeln]

Hallo Ienoide,
vielen Dank das Du Dich gemeldest hast.Ich dachte schon ich bin der einzige der sich für diese Firma interessiert.
Ich schätze mal Kurse um die 12 Euro sind nicht mehr weit weg vorausgesetzt der Gesamtmarkt macht mit.Wir müssen eben noch etwas Gedult haben.Die Pipeline ist auf jeden
Fall gut gefüllt und für diesen Bereich sind die Aussichten ja nicht schlecht.

Bis bald
Gruß knudeln

[knudeln]

Hallo,das Handelsvolumen steigt und es geht schön langsam und besonnen nach oben.

[knudeln]

Hallo,
das Handelsvolumen steigt und es geht seit Tagen schön langsam und besonnen nach oben.Im Moment bei 8,95 im Amiland.Die Produktpipeline ist sehr gut bestückt,sämtliche Infos über das Unternehmen auf der Hompepage von Nektar Therapheutics nachzulesen.
Wertpapiernr:165417!!!!

Wer ist noch investiert.

Gruß knudeln.................................

[Plaste]

Hallo knudeln,

ich bin seit ca 1 Jahr dabei.
Leider hatte ich bei der Kurshalbierung nicht noch mal nach gekauft.
Nektar ist für mich, wie die meisten meiner Positionen, langfristig. Ich warte eigentlich schon einige Zeit darauf, das das alternativ verabreichte Insulin ("Spray) auf den Markt kommt.
Wenn sich das durchsetzen sollte, ist der jetzige Kurs ein reiner Witz. Aber Nektar hat ja noch einiges mehr zu bieten.
mfg Plaste

[knudeln]

Hallo Plaste,
ich bin ganz Deiner Meinung!Da bin ich froh nicht als einziger von dem Wert überzeugt zu sein.Wenn das mit dem Spray marktreif ist wird Nektar auch bei uns bekannt.Also viel Glück noch und auf weiterhin so schön steigende Kurse wie die letzten sechs Tage.

Gruß knudeln

[knudeln]

Hallo Nektargemeinde,es geht seit Tagen nur nach Norden!!!
So könnte es immer bleiben.Diese Beständigkeit ist beeindruckend.Es wird Zeit für ein paar News so wird es in den nächsten Tagen mal wieder einen großen Sprung geben.

Tschau meldet euch mal wieder!!!
Aktuell 9,80 im Amiland



Gruß knudeln

[Plaste]

Hallo Nektarianer,

na, 14% gestern. Gabs News oder hab ich was verpaßt?

[Plaste]

Na, noch jemand dabei?
Übrigens schon mal auf die HP geschaut?

Termine die von Interesse sein könnten:

- Feb. 4 Merrill Lynch Conference "Nektar Update" New York, NY

- Feb. 23-25 BIO CEO and Investor Conference "Nektar Update" New York, NY

- March 3-5 Lehman Brothers Conference "Nektar Update" Miami, Florida

- Wenn ich die News vom 21.01.04 richtig gelesen habe, soll das 4. Quartal am 31.12.03 geendet haben und am 02.02.04 ein "conference call for analysts and investors beginning"

Na hoffen wir das beste.

mfg Plaste

[Plaste]

Hallo Monolog...

"Stocks to Watch:

Nektar Therapeutics: Extragewinn sorgt für schwarze Zahlen

03.02.2004 -
Im abgelaufenen Quartal hat die Gesellschaft einen Gewinn von 3,51 Mio. Dollar erzielt, was 6 Cent je Aktie entspricht. Darin enthalten sind Sondereffekte von 26,9 Mio. Dollar. Im vergleichbaren Vorjahresviertel hat die Gesellschaft einen Verlust von 31,1 Mio. Dollar bzw. 56 Cent je Anteilsschein erzielt. Der Umsatz ist um 13 Prozent auf 25,6 Mio. Dollar gestiegen.

Erfolgreich investieren mit unserem Börsenbrief 4investors weekly."

[leonide]

Hallo,
gute Neuigkeiten, es geht voran, sowohl im Kurs, als auch in den news.
Ich bin drin und bleib drin!
leonide

Nektar Reports that Pfizer and Aventis Seek Approval to Market Exubera® in Europe


San Carlos, CA

March 04, 2004

Nektar Therapeutics (Nasdaq:NKTR) today reported that Pfizer Inc. and Aventis announced that the European Medicines Evaluation Agency (EMEA) has accepted the filing of a marketing authorization application for Exubera® (inhaled human insulin powder). The filing was submitted by Pfizer and Aventis and the acceptance of the filing was reported by them today. Nektar develops and provides the inhalers and the powdered insulin for the Exubera product.

Pfizer and Aventis seek approval to market Exubera for adult patients with type 1 and type 2 diabetes. The two companies have been working with the US Food and Drug Administration to determine the appropriate timing for submission of the Exubera new drug application in the United States.

Exubera is a dry powder form of insulin that is inhaled into the lungs prior to eating. Inhaled insulin closely mimics the normal physiological insulin response to meals, by quickly being absorbed into the bloodstream to reduce meal-related spikes in glucose levels.

It is estimated that nearly 150 million people worldwide suffer from diabetes, and the number is expected to rise to 300 million people in the next 20 years. Complications commonly associated with uncontrolled or poorly controlled diabetes include heart disease, stroke, kidney failure and blindness. Currently, diabetes and its complications account for more than $100 billion in healthcare costs annually in the United States.

Exubera is being developed for patients with type 1 and type 2 diabetes through a collaboration between Pfizer Inc and Aventis. The two companies have entered into a global agreement to co-develop, co-promote (where permitted by local law) and co-manufacture inhaled insulin. Pfizer is also in collaboration with Nektar Therapeutics, developers of the inhalation device and formulation.

About Nektar Therapeutics
Nektar Therapeutics provides industry-leading drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics. Nektar’s advanced drug delivery capabilities are designed to enable the company’s biotechnology and pharmaceutical partners to solve drug development challenges and realize the full potential of their therapeutics, from development of new molecular entities to managing the lifecycles of established products.

This release contains forward-looking statements that reflect management’s current views as to Nektar’s business strategy, product and technology development plans and funding, collaborative arrangements, clinical trials, and other future events and operations. These forward-looking statements involve uncertainties and other risks that are detailed in Nektar’s reports and other filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2002, as amended and its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2003. Actual results could differ materially from these forward-looking statements.

[Plaste]

Hallo Leonide,

ich bin natürlich auch noch drin, und bleibe drin.
Warten wir mal die Reaktionen die Tage ab.
Ich gehe von weiter steigenden Kursen aus.

mfg Plaste

[Plaste]

05.03.2004
Nektar Therapeutics neues Kursziel
Deutsche Securities

Rating-Update:

Die Analysten vom Investmenthaus Deutsche Securities stufen die Aktie von Nektar Therapeutics (ISIN US6402681083/ WKN 165417) unverändert mit "buy" ein. Das Kursziel sei von 24 auf 30 USD erhöht worden.


http://www.aktiencheck.de/analysen/default_an.asp?sub=7&page…

Das Sie bei 21,70 USD sind, ist ja noch ein Stück übrig.

mfg Plaste

[Plaste]

Hallo Leute, alle noch dabei?
Nach dem es ja nun einige Zeit gen Süden ging, scheint sich die Lage nun zu bessern. Und hier mal wieder was neues:



May 26, 2004 06:30 AM US Eastern Timezone

SciClone Announces Collaboration to Develop Pegylated ZADAXIN

BIOWIRE2K

SAN MATEO, Calif.--(BUSINESS WIRE)--May 26, 2004--SciClone Pharmaceuticals, Inc. (Nasdaq:SCLN) today announced that it has entered into a collaborative agreement with Nektar Therapeutics` (Nasdaq:NKTR) subsidiary, Nektar Therapeutics, AL Corporation to develop a pegylated formulation of ZADAXIN(R). Nektar will apply its Advanced PEGylation technology to ZADAXIN with the objective of improving the therapeutic use and potential efficacy of the compound. SciClone has filed for worldwide patent protection for the composition-of-matter of pegylated ZADAXIN.

Dr. Cynthia Tuthill, Vice President of Scientific Affairs at SciClone commented, "We are very pleased to be working with Nektar, a recognized leader in the field of pegylation technology, on this significant initiative." If the formulation is successful, pegylated ZADAXIN could lead to improved patient compliance due to less frequent dosing and would allow the drug to remain in the body at a higher concentration level for a longer period of time. In addition to potentially enhancing the use of ZADAXIN in the treatment of hepatitis C and hepatitis B, SciClone believes that a pegylated formulation also could broaden the potential application of ZADAXIN in cancer therapy.

About Nektar Advanced PEGylation

Nektar Advanced PEGylation, developed by Shearwater, now part of Nektar, is based on the use of non-toxic polyethylene glycol (PEG) polymers, which can be attached to most major drug classes, including proteins, peptides, antibody fragments, small molecules, and other drugs. Nektar Advanced PEGylation has the potential to improve the safety and efficacy of therapeutic agents by increasing drug circulation time in the bloodstream, increasing bioavailability, decreasing immunogenicity, decreasing dosing frequency, and improving drug solubility and stability.

About SciClone

SciClone Pharmaceuticals is a biopharmaceutical company engaged in the development of therapeutics to treat life-threatening diseases. SciClone is currently evaluating its lead product ZADAXIN in several clinical trials, including two phase 3 hepatitis C clinical trials in the U.S., a completed phase 3 hepatitis B clinical trial in Japan, a phase 2 malignant melanoma clinical trial in Europe, two phase 2 liver cancer pilot studies in the U.S., a hepatitis C triple therapy open-label clinical trial in Mexico, and a hepatitis B combination therapy trial in Taiwan. SciClone recently announced plans for a ZADAXIN phase 3 hepatitis C triple therapy clinical trial in Europe. The Company`s other principal drug development candidate is SCV-07, a potentially orally available therapeutic to treat viral and infectious diseases. For more information about SciClone, visit www.sciclone.com.

About Nektar Therapeutics

Nektar Therapeutics provides industry-leading drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics. Nektar`s advanced drug delivery capabilities are designed to enable the company`s biotechnology and pharmaceutical partners to solve drug development challenges and realize the full potential of their therapeutics, from developing new molecular entities to managing the life cycles of established products.


Quelle: http://home.businesswire.com/portal/site/biospace/index.jsp?…

[Plaste]

May 28, 2004 09:00 AM US Eastern Timezone

Friedman Billings Ramsey to Webcast Nektar Presentation at 8th Annual Growth Investor Conference

8th Annual Growth Investor Conference

SAN CARLOS, Calif.--(BUSINESS WIRE)--May 28, 2004--Nektar Therapeutics (Nasdaq:NKTR) announced today that Friedman Billings Ramsey will Webcast the company`s corporate presentation at its 8th annual Growth Investor Conference on Thursday, June 3rd at 9:20 a.m. Eastern time. The presentation by Dr. Christopher Searcy, Nektar vice president, corporate development, may be accessed on the Investor Relations site of Nektar`s Web site at www.nektar.com and will be available until June 17th.

Nektar Therapeutics provides industry-leading drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics. Nektar`s advanced drug delivery capabilities are designed to enable the company`s biotechnology and pharmaceutical partners to solve drug development challenges and realize the full potential of their therapeutics, from developing new molecular entities to managing the life cycles of established products.

Quelle: http://home.businesswire.com/portal/site/biospace/index.jsp?…

[Plaste]

http://www.nektar.com/content/pr_1086625831


Nektar Reports that New Long-Term Safety and Efficacy Data on EXUBERA® (Human Insulin Powder) Presented at American Diabetes Association Scientific Sessions

Orlando, FL

June 07, 2004

Nektar Therapeutics (Nasdaq:NKTR) reported today that Pfizer and Aventis announced results of long-term studies showing sustained glycemic control and pulmonary function in patients with type 2 diabetes taking EXUBERA®, an inhalable, rapid-acting dry powder insulin.1,2 Nektar developed the inhalers and the powdered insulin formulation for the EXUBERA® product. These new data were presented this weekend at the 64th Annual Scientific Sessions of the American Diabetes Association.

A pooled analysis of two one-year open-label studies involving 627 patients with type 2 diabetes showed that patients who added EXUBERA® to their treatment regimen experienced no clinically important effect on pulmonary function compared with patients treated with oral agents alone.1 Glycemic control was maintained in both arms.1 An additional analysis of 209 patients, 159 of whom were treated with EXUBERA® for up to four years, further supported these findings in type 1 and type 2 patients treated with EXUBERA®.2

Nektar pulmonary technologies integrate customized formulation and proprietary fine-powder processing and packaging technologies with a proprietary inhalation device for efficient, reproducible, and convenient deep-lung drug delivery. Beyond EXUBERA®, Nektar envisions applying its Pulmonary Technology to address additional unmet therapeutic needs, including, targeted treatment of lung disorders, a non-invasive alternative to injection for macromolecules such as peptides and proteins, and applications where faster onset of action is desired. Providing a non-invasive alternative to injection and rapid action for otherwise slow-acting oral therapies, the pulmonary delivery route offers opportunities for improved and innovative drug delivery and greater patient compliance.

“The results of these studies suggest that EXUBERA® may be effective and well-tolerated in this patient group,” said Anthony Barnett, M.D., lead study investigator and Professor of Medicine, University of Birmingham, United Kingdom. “In addition, the results suggest that changes in pulmonary function are small, similar between treatment groups and non-progressive.”

In addition, subanalyses of these studies focused on treatment satisfaction of patients failing oral agents. Among uncontrolled patients with a Hemoglobin A1C (HbA1c) of more than 9.5 percent, those who received EXUBERA® showed improved glycemic control from baseline and higher overall patient satisfaction compared with those patients receiving additional oral agents.3,4 HbA1C level reflects blood glucose readings over a period of a few months.

“In these studies, patients were able to successfully incorporate EXUBERA® into their daily treatment regimen,” said Marcia A. Testa, M.P.H., Ph.D., Senior Lecturer, Harvard School of Public Health and lead investigator for the studies. “The profile of EXUBERA®, coupled with our new data showing patients’ preference of inhaled insulin over oral agents, suggest that EXUBERA® may be a promising treatment option for patients with diabetes.”

Insulin is the standard of care for people with type 1 diabetes. More than 30 percent of those with type 2 diabetes will eventually need insulin.5 Treatment with insulin typically includes multiple daily injections which can affect compliance.6 When available, inhaled insulin may assist patients to achieve glycemic control without additional injections.7

EXUBERA® is being developed for use in patients with type 1 and type 2 diabetes through a collaboration between Pfizer Inc and Aventis. The two companies have entered into a global agreement to co-develop, co-promote (where permitted by local law) and co-manufacture inhaled insulin. Pfizer is also in collaboration with Nektar Therapeutics, developers of the inhalation device and formulation process. EXUBERA® was submitted to the European Medicine Evaluation Agency (EMEA) in early 2004.

Pfizer Inc (NYSE: PFE) discovers, develops, manufactures and markets leading prescription medicines for humans and animals, and many of the world’s best-known consumer products.

Aventis is dedicated to treating and preventing disease by discovering and developing innovative prescription drugs and human vaccines. In 2003, Aventis generated sales of € 16.79 billion, invested € 2.86 billion in research and development and employed approximately 69,000 people in its core business. Aventis corporate headquarters are in Strasbourg, France. For more information, please visit: www.aventis.com.

Nektar Therapeutics, San Carlos, Calif., provides industry-leading drug delivery technologies, expertise and manufacturing to enable the development of high-value, differentiated therapeutics. Nektar’s advanced drug delivery capabilities are designed to enable the company’s biotechnology and pharmaceutical partners to solve drug development challenges and realize the full potential of their therapeutics, from developing new molecular entities to managing the life cycles of established products. For more information, please visit: www.nektar.com.

This release contains forward-looking statements that reflect management’s current views as to Nektar’s business strategy, product and technology development plans and funding, collaborative arrangements, clinical trials, and other future events and operations. These forward-looking statements involve uncertainties and other risks that are detailed in Nektar’s reports and other filings with the SEC, including its Annual Report on Form 10-K, as amended, for the fiscal year ended December 31, 2003. Actual results could differ materially from these forward-looking statements.

References

1. Barnett AH, et al. “Efficacy and One-year Pulmonary Safety of Inhaled Insulin (EXUBERA®) as Adjunctive Therapy with Metformin or Glibenclamide in Type 2 Diabetes Patients Poorly Controlled on Oral Agent Monotherapy.” Poster presented at 64th Annual Scientific Sessions, American Diabetes Association, Orlando, FL, June 2004.
2. Skyler J, et al. “Sustained Long-term Efficacy and Safety of Inhaled Insulin During Four Years of Continuous Therapy.” Poster presented at 64th Annual Scientific Sessions, American Diabetes Association, Orlando, FL, June 2004.
3. Testa MA, et al. “Quality of Life (QOL) Improvements in Type 2 Diabetes When EXUBERA® Is Added After Failure on Metformin Monotherapy: An International Phase 3 Trial.” Poster presented at 64th Annual Scientific Sessions, American Diabetes Association, Orlando, FL, June 2004.
4. Testa MA, et al. “Satisfaction and Quality of Life with Sulfonylurea Plus Either Metformin or EXUBERA®: An International Randomized Phase 3 Trial.” Poster presented at 64th Annual Scientific Sessions, American Diabetes Association, Orlando, FL, June 2004.
5. Dunning, T, et al. “Insulin Delivery Devices.” Australian Prescriber, 2002;25:136-138.
6. Owens DR, et al. “Alternative Routes of Insulin Delivery.” Diabetic Medicine, 2003;20:886-898.
7. Johnson, FR, et al. “Trading Health for Convenience: Diabetes Patients’ Stated Preference for Insulin Therapies.” Poster presented at 64th Annual Scientific Sessions, American Diabetes Association, Orlando, FL, June 2004.